Prevalence and risk factors of methicillin-resistant *Staphylococcus aureus* colonization among HIV patients in Mekelle, Northern Ethiopia

Goyitom Gebremedhn1,2, Tewelde Tesfay Gebremariam1, Araya Gebreyesus Wasiun1, Tsehaye Asmelash Dejene1 and Muthupandian Saravanan1*

**Background**

Methicillin resistant *Staphylococcus aureus* (MRSA), causes severe and fatal infections such as bloodstream infections, infective endocarditis, pneumonia, skin and soft tissue infections and is a global health issue (National Clinical Effectiveness Committee 2013). Though MRSA can infect all patients, HIV infected patients are more susceptible to MRSA due to their compromised immune system (Hidron et al. 2010; Lee et al. 2005; Bozzett et al. 2001).

The anterior nares are the most consistent site for MRSA colonization (Otto 2012; Wertheim et al. 2005), yet it can also colonize the axilla, inguinal region, throat,
oropharynx, wounds and gastrointestinal tract (Otto 2012; Eveillard et al. 2006; Shahin et al. 1999).

MRSA transmission is mainly by direct contact through transient carriage from the hands of health care workers, contaminated equipment or with contaminated environmental surfaces (Lowy 1998).

MRSA infections have become increasingly problematic in both health care and community settings, leading to a greater morbidity, mortality, longer hospital stays, prolonged antibiotic administration and increased treatment costs (Government of Western Australia Department of Health 2013; Wertheim et al. 2005; Filice et al. 2010; Edem et al. 2013). Existing literatures show that, HIV patients are six to 18-fold more susceptible to MRSA than the general population, and is the main cause of bacteremia and endocarditis in these patients (Popovich et al. 2010; Tumbarello et al. 2002; Burkey et al. 2008; Furuno et al. 2011; Franzetti 2006).

There are few studies on MRSA colonization in HIV negative individuals in Ethiopia (Shibabaw et al. 2013; Kejela and Bacha 2013). However, there are no data on the prevalence and risk factors for MRSA colonization among HIV patients in the country. Therefore, this study was conducted to fill the existing knowledge gap by determining the nasal and throat colonization of MRSA and related risk factors in HIV-infected persons.

**Methods**

**Study design, study period and study area**

A cross-sectional study was conducted from September 2014 to February 2015 in three selected health centers and one hospital giving HIV care services, namely Kasech Health Center, Mekelle Health Center, Semen Health Center and Mekelle Hospital. These health facilities were (as the report on September 2014) providing HIV care services for a total of 5989 HIV-positive patients.

**Sample size**

It was determined by taking the prevalence of MRSA from South Africa, which was 21 % (Heysell et al. 2011) using the following formula: $n = \frac{Z^2 \alpha}{2 \pi (1 - \pi)}$, \((1.96)^2 \times 0.21(1 - 0.21) = 249.\)

\[d^2(0.05)^2\]

A proportionate allocation formula (Pandey and Verma 2008) was used to determine the sample size from each health facility.

\[n_j = \frac{n}{N} N_j \quad j = 1, 2, 3, k\]

where, \(k\) is the number of strata and \(n_j\) is sample size of the \(j\)th stratum
\(N_j\) is population size of the \(j\)th stratum
\(n = n_1 + n_2 + ... + n_k\) is the total sample size
\(N = N_1 + N_2 + ... + N_k\) is the total population size

The sample size of each health facility is calculated as:

\(n_1\) (Mekelle Hospital) = 160; \(n_2\) (Kasech Health center) = 28; \(n_3\) (Semen Heath Center) = 25 and \(n_4\) (Mekelle Health Center) = 43.
Data sources and data collection
A well structured questionnaire in combination with a review of medical records were used to collect socio-demographic, risk factors and clinical characteristics of HIV positive individuals. Information collected include age, sex, hospitalization in the past 6 months, hospital visit in the past 12 months, under five children staying in daycare centers, homeless (current or past), prison (current or past), surgery in the past 1 year, household member’s hospitalization in the past 1 year, presence of percutaneous device in the past 1 year, oral antibiotic usage in the past 3 months, current use of Co-trimoxazole, most recent CD4 count.

Specimen collection, transportation, culturing and bacterial isolation
Nasal and throat swabs were collected using sterile cotton swabs pre-moistened with sterile normal saline using the standard procedure (D’Avila et al. 2008; Kumar et al. 2013; Dhuria et al. 2013). Nasal specimens were obtained by rotating a single swab 2–3 times around the inside of the anterior nares, whereas throat specimens were obtained by swabbing the posterior pharynx and lateral walls of the pharynx (tonsillar area), without touching the buccal mucosa or tongue. Swabs were then inoculated into the Stuart’s Transport media and transported to the Ayder referral hospital medical microbiology laboratory within 3–4 h. Swabs were inoculated onto Mannitol Salt Agar (MSA) (Oxiod, Hampshire, UK) and incubated at 37 °C aerobically for 24 h. After incubation, yellowish colonies from the MSA plate were sub-cultured to Nutrient Agar (Oxiod, Hampshire, UK) for further biochemical characterization. Bacterial identification was done based on colony morphology, color of the colonies and the tube coagulase test. MRSA isolates were identified using Cefoxitin disc by the Kirby-Bauer disk diffusion method (CLSI 2013).

Antimicrobial susceptibility pattern of MRSA to other antibiotics
The antimicrobial susceptibility testing of MRSA was detected using the modified Kirby-Bauer disk diffusion method according to the clinical laboratory standard institute (CLSI) guidelines (CLSI 2013). The following antimicrobials were used in their respective concentration: Ciprofloxacin (5 μg), Trimethoprim-Sulfamethoxazole (1.25/23.75 μg), Erythromycin (15 μg), Clindamycin (2 μg), and Amikacin (30 μg) (Hi-Media, India). These antimicrobials were selected based on the local usage to treat MRSA and considering the recommended antimicrobial agents for MRSA infections.

Data processing and analysis
Variables from the demographic and clinical data obtained from the questionnaire and laboratory data were cleaned and entered into a computer. Statistical analysis was done using SPSS version 20.0 for windows. $X^2$ (Chi square) test was used to determine the association of risk factors. $P < 0.05$, considered as statistically significant and multivariate analysis was used to differentiate the independent risk factors for $S. aureus$ colonization.

Quality control
Standard operating procedures (SOPs) were followed during sample collection, transportation, and processing steps. The quality of the culture media and antimicrobial disks
were thoroughly checked using standard American Type Culture Collection (ATCC) reference strain of *S. aureus* ATCC 25923 obtained from Ethiopian Health and Nutritional Research Institute (EHNRI).

**Ethical clearance**

This study was ethically approved by the Ethical Review Committee (Ref. No-ERC0453/2014), College of Health Science Mekelle University. Written consent was obtained from the study participants or guardians. Patients who were positive for MRSA were contacted by the respective doctors for further management. All information of participants were kept confidential.

**Results**

A total of 249 HIV positive individuals attending HIV care service in four health facilities were included in the study. The majority of the participants were females 174 (69.9 %). The age range of participants were 5–72 years with a mean age of 35 years. The majority 103 (41.4 %) of the participants were in the age group of 30–39 (Table 1). The overall rate of *S. aureus* and MRSA colonization among the 249 study participants were 81 (32.5 %) and 6 (2.4 %) respectively. Distribution of MRSA by nasal, throat and both sites were 3, 2, 1 respectively and for *S. aureus* was 41 (50.6 %), 28 (34.6 %) and 12 (14.8 %) respectively.

**Analysis of risk factors for *S. aureus* and MRSA colonization**

Variables assessed as risk factors and found with a frequency of less than 10 % of the total 249 participants were excluded from the statistical analysis of risk factors for *S. aureus*. These include child aged under 5 years (0), homeless (4), prisoners (2), surgery in the past 1 year (3), recent intravenous antibiotic usage (0) and HIV positive individuals who have not started antiretroviral therapy (Pre-ART) (7). Two of the homeless, one of these previously prisoners, and two of these Pre-ART HIV patients were colonized with *S. aureus*. MRSA was not isolated from the prisoners, those with surgery in the past one year, and pre-ART, HIV patients, whereas one person among the homeless participants was colonized with MRSA.

Individuals in the age group of 70–79 years were more colonized by *S. aureus*; however, there was no statistical significance (p = 0.59) (Table 1). All the six MRSA was isolated from the age groups of 20–49 years (Table 2). *S. aureus* colonization rate was higher among females 62 (35.6 %) as compared to males 19 (25.3 %). However, this was not statistically significant (p = 0.113) (Table 1). All MRSA isolates 6 (3.4 %) were from females (Table 2).

*Staphylococcus aureus* colonization rate was statistically significant in individuals with the history of hospitalization, percutaneous device usage within the past 1 year, patients with a household member’s hospitalization within past 12 months and patients with CD4 count lower than 200 cells/mm³ (p < 0.05) (Table 1). Similarly, MRSA colonization was higher in patients with a history of hospitalization (Table 2). Risk factors for the colonization of *S. aureus* with statistical significance in the bivariate analysis were further analyzed using multivariate analysis and were found to be significantly associated (Table 3).
Antimicrobial susceptibility pattern of MRSA isolates

Antimicrobial susceptibility testing was performed on the six MRSA isolates against the commonly used antibiotics. Accordingly, 16.7, 33.3 and 50 % resistance were observed against Ciprofloxacin, Trimethoprim-Sulphamethoxazole, Clindamycin and Erythromycin respectively. Interestingly, all the isolates have shown 100 % sensitivity to Amikacin. However, three of the MRSA isolates (50 %) have shown multidrug resistance and all of them were isolated from HIV patients in hospital.

Table 1 Analysis of risk factors for Nasal and Throat colonization of S. aureus in HIV positive individuals attending HIV care service in Northern Ethiopia, September 2014–February 2015

| Variables                                      | Frequency (%) | S. aureus colonization |
|------------------------------------------------|---------------|------------------------|
|                                                |               | No. (%)                | OR (95 % CI)       | P value |
| Age in years                                   |               |                        |                     |         |
| 1–9                                            | 10 (4.0)      | 1 (10)                 | NC                  | 0.59    |
| 10–19                                          | 19 (7.6)      | 8 (42.1)               |                     |         |
| 20–29                                          | 35 (14.1)     | 10 (28.6)              |                     |         |
| 30–39                                          | 103 (41.4)    | 36 (35.0)              |                     |         |
| 40–49                                          | 55 (22.1)     | 18 (32.7)              |                     |         |
| 50–59                                          | 17 (6.8)      | 5 (29.4)               |                     |         |
| 60–69                                          | 7 (2.8)       | 1 (14.3)               |                     |         |
| 70–79                                          | 3 (1.2)       | 2 (66.7)               |                     |         |
| Sex                                            |               |                        |                     |         |
| Female                                         | 174 (69.9)    | 62 (35.6)              | 0.613 (0.334–1.123) | 0.113   |
| Male                                           | 75 (30.1)     | 19 (25.3)              |                     |         |
| Hospitalization in the past 6 months           |               |                        |                     |         |
| No                                             | 223 (89.6)    | 60 (26.9)              | 11.41 (4.12–31.62)  | 0.000   |
| Yes                                            | 26 (10.4)     | 21 (80.8)              |                     |         |
| Hospital visit in the past 12 months           |               |                        |                     |         |
| No                                             | 61 (24.5)     | 28 (45.9)              | 0.463 (0.255–0.839) | 0.011   |
| Yes                                            | 188 (75.5)    | 53 (28.2)              |                     |         |
| Household member’s hospitalization in the past 1 year |     |                        |                     |         |
| No                                             | 224 (90)      | 60 (26.8)              | 14.35 (4.732–43.516) | 0.000   |
| Yes                                            | 25 (10)       | 21 (84.0)              |                     |         |
| Presence of percutaneous device in the past 1 year |             |                        |                     |         |
| No                                             | 189 (75.9)    | 33 (17.5)              | 18.91 (9.061–39.46) | 0.000   |
| Yes                                            | 60 (24.1)     | 48 (80.0)              |                     |         |
| Oral antibiotic usage in the past 3 months     |               |                        |                     |         |
| No                                             | 181 (72.7)    | 50 (27.6)              | 2.195 (1.232–3.912) | 0.08    |
| Yes                                            | 68 (27.3)     | 31 (45.6)              |                     |         |
| Current use of trimethoprim-sulphamethoxazole  |               |                        |                     |         |
| No                                             | 161 (64.7)    | 24 (27.3)              | 1.462 (0.827–2.583) | 0.192   |
| Yes                                            | 88 (35.3)     | 57 (35.4)              |                     |         |
| Most recent CD4 count                          |               |                        |                     |         |
| <200                                           | 37 (14.9)     | 21 (56.8)              | 1.00                | 0.004   |
| 200–500                                        | 109 (43.8)    | 33 (30.3)              | 0.331 (0.153–0.713) | 0.005   |
| >500                                           | 103 (41.4)    | 27 (26.2)              | 0.271 (0.123–0.593) | 0.001   |

The percent (%) of S. aureus colonization is the proportion of each category
R reference category
Discussion

Our result indicates that the prevalence of *S. aureus* 81 (32.5%) and MRSA 6 (2.4%) was lower than similar studies conducted in San Francisco 55.2% for *S. aureus* and 27.6% for MRSA (Miller et al. 2003) and India 50.7–81% for *S. aureus* and 18.3–42% for MRSA (Dhuria et al. 2013). MRSA prevalence of 2.4% was similar to the 5.1% reported from Singapore (Kyaw et al. 2012). However, it was lower than report from other African nations with a rate of 20% in Nigeria (Edem et al. 2013) and 21% in Kwazu Natal Hospital South Africa (Heysell et al. 2011).

| Variables                                      | Frequency (%) | MRSA colonization No. (%) |
|------------------------------------------------|---------------|---------------------------|
| **Variables**                                   |               |                          |
| Age in years                                   |               |                          |
| 1–9                                            | 10 (4.0)      | 0 (0)                    |
| 10–19                                          | 19 (7.6)      | 0 (0)                    |
| 20–29                                          | 35 (14.1)     | 2 (5.7)                  |
| 30–39                                          | 103 (41.4)    | 3 (2.9)                  |
| 40–49                                          | 55 (22.1)     | 1 (1.8)                  |
| 50–59                                          | 17 (6.8)      | 0 (0)                    |
| 60–69                                          | 7 (2.8)       | 0 (0)                    |
| 70–79                                          | 3 (1.2)       | 0 (0)                    |
| Sex                                            |               |                          |
| Female                                         | 174 (69.9)    | 6 (3.4)                  |
| Male                                           | 75 (30.1)     | 0 (0)                    |
| Hospitalization in the past 6 months           |               |                          |
| No                                             | 223 (89.6)    | 4 (1.8)                  |
| Yes                                            | 26 (10.4)     | 2 (7.7)                  |
| Hospital visit in the past 12 months           |               |                          |
| No                                             | 61 (24.5)     | 2 (3.3)                  |
| Yes                                            | 188 (75.5)    | 4 (2.1)                  |
| Household member hospitalization in the past 1 year |           |                          |
| No                                             | 224 (90)      | 4 (1.8)                  |
| Yes                                            | 25 (10)       | 2 (8.0)                  |
| Presence of percutaneous device in the past 1 year |           |                          |
| No                                             | 189 (75.9)    | 2 (1.1)                  |
| Yes                                            | 60 (24.1)     | 4 (6.7)                  |
| Oral antibiotic usage in the past 3 months     |               |                          |
| No                                             | 181 (72.7)    | 3 (1.7)                  |
| Yes                                            | 68 (27.3)     | 3 (4.4)                  |
| Current use of trimethoprim-sulfamethoxazole   |               |                          |
| No                                             | 161 (64.7)    | 2 (2.3)                  |
| Yes                                            | 88 (35.3)     | 4 (2.5)                  |
| Most recent CD4 count                          |               |                          |
| <200                                           | 37 (14.9)     | 3 (8.1)                  |
| 200–500                                        | 109 (43.8)    | 1 (0.9)                  |
| >500                                           | 103 (41.4)    | 2 (1.9)                  |

The percent (%) of MRSA colonization is the proportion of each category relative to the reference category.
The low prevalence of *S. aureus* and MRSA colonization in our study might be due to the rare visit of these HIV patients to the health facilities, since repeated visits to health care centers, or contact with hands of health care workers in HIV infected individuals is the major risk factor for the colonization (Hidron et al. 2010; Lowy 1998; Government of Western Australia Department of Health 2013).

In our study, the inclusion of throat swabs increased the sensitivity of nasal screening of *S. aureus* and MRSA by 34.6 and 33.3%, respectively, which was also shown by other studies conducted in Bristol, UK (Chow et al. 2012), Singapore (Kyaw et al. 2012) and Switzerland (Mertz et al. 2007).

In this study, recent hospitalization was associated with *S. aureus* colonization. This was also showed by other studies conducted in Singapore (Kyaw et al. 2012; Villacian et al. 2004) and TX, USA (Onorato et al. 1999). *S. aureus* and MRSA colonization rate was higher among those who visited hospitals, in the last twelve months; this is in line with the result of other study conducted in Singapore (Kyaw et al. 2012). Presence of percutaneous device within the past year was found to have a strong association with *S. aureus* and MRSA colonization. This result was supported by other studies conducted in Singapore (Kyaw et al. 2012) and in TX, USA (Onorato et al. 1999).

MRSA colonization was higher in those with Low CD4 count (less than 200/mm$^3$) which was also shown by other studies conducted in Singapore (Villacian et al. 2004) and in Dallas, TX, USA (Cenizal et al. 2008). In our study the antimicrobial susceptibility pattern of MRSA isolates showed 100 % sensitivity to Amikacin which was similar to the study in India (Dhuria et al. 2013).

### Conclusions

In this study there was a lower prevalence of MRSA; however, high degree of *S. aureus* colonization among the HIV patients. History of hospitalization, percutaneous device usage, patients with a household member’s hospitalization and CD4 count lower than 200 cells/mm$^3$ were significantly associated with *S. aureus* colonization. MRSA isolates from HIV patients in hospital were more resistant than MRSA isolates obtained from health centers. All MRSA isolates were 100 % sensitive to Amikacin.

### Table 3 Multivariate analysis of independent risk factors associated with *S. aureus* colonization among HIV positive individuals attending HIV care service in Northern Ethiopia, September 2014–February 2015

| Risk factors                                      | AOR (95 % CI)   | P value |
|--------------------------------------------------|-----------------|---------|
| Hospitalization in the past 6 months             | 9.97 (2.69–36.87) | 0.001   |
| Hospital visit in the past 12 months              | 0.31 (0.14–0.697) | 0.004   |
| Presence of percutaneous device in the past 1 year| 20.695 (8.75–48.96) | 0.000   |
| Family member’s hospitalization in the past 1 year| 12.97 (3.48–48.30) | 0.000   |
| Most recent CD4 count                        |                 |         |
| <200                                             |                 |         |
| 200–500                                           | 0.33 (0.12–0.91) | 0.033   |
| >500                                              | 0.22 (0.08–0.6)  | 0.004   |

AOR adjusted odds ratio
Authors’ contributions
GG was the principal investigator, conceived the study, designed and data collection, laboratory works, data analyzed and drafted the manuscript for publication. MS was the Principal advisor for this study, designed the complete study, data collection, laboratory works, data analyzed and prepared for final version of the manuscript for publication. TT was the Co-Advisor, contributed designing of the study, data collection, Laboratory works and data analysis. AG and TA prepared and reviewed the initial and final draft of the manuscript. All authors read and approved the final manuscript.

Author details
1 Department of Medical Microbiology and Immunology, Institute of Biomedical Science, College of Health Sciences, Mekelle University, 1871 Mekelle, Ethiopia. 2 Tigray Regional State Health Bureau, Mekelle, Ethiopia.

Acknowledgements
We would like to acknowledge to the Tigray Regional Health Bureau and Tigray Health and Research Laboratory for financial and resource support. We would also like to acknowledge Mekelle Hospital, Mekelle Health center, Kavech health center and Semen Health center to conduct this study in the health facilities. We greatly acknowledge staff members of the ART clinic in each health facilities for their support during data collection and to the study participants. We would like to thank to the staff of microbiology laboratory of the Ayder Referral Hospital and Mekelle University.

Competing interests
The authors declare that they have no competing interests.

Received: 9 October 2015   Accepted: 17 June 2016
Published online: 24 June 2016

References
Bozzette SA, Joyce G, Mccaufrey DF, Leibowitz AA, Morton SC, Berry SH et al (2001) Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med 344:817–823
Burkey MD, Wilson LE, Moore RD, Lucas GM, Francis, J, Gebo KA (2008) The incidence of and risk factors for MRSA bacteremia in an HIV-infected cohort in the HAART era. HIV Med 9:858–862
Cenizal MJ, Hardy RD, Anderson M, Kathy Katz BS, Skiest DJ (2008) Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus (MRSA) nasal colonization in HIV-infected ambulatory patients. J Acquir Immune Defic Syndr 48:567–571
Chow A, Win MK, Wong CS, Leo YS (2012) Universal methicillin-resistant Staphylococcus aureus (MRSA) screening: comparison of anatomic screening sites for patients with high and low prevalence of MRSA carriage. Infect Control Hosp Epidemiol 33:315–317
CLSI (2013) Performance standards for antimicrobial susceptibility testing. CLSI approved standard M100-S23. Clinical and Laboratory Standards Institute, Wayne
D’Avila NE, Zhang L, Miller RG, D’Avila AC, Conceição AP, Boffo MS (2008) High prevalence of nasopharyngeal colonization by Staphylococcus aureus among children with HIV-1 infection in extreme southern Brazil. J Trop Pediatr 54(6):410–412
Dhuria N, Devi P, Devi B, Malhotra S (2013) Prevalence and risk factors for methicillin-resistant Staphylococcus aureus colonization in anterior nares of HIV-positive individuals. Wudpecker J Med Sci 2:026–029
Edem EN, Onwuezobe IA, Ochag EA, Etok CA, Eyakndue EO (2013) Antibiogram of nasal isolates of Staphylococci in anterior nares of human immunodeficiency virus patients in the University of Uyo Teaching Hospital (UUTH) Uyo, Akwa Ibom State, Nigeria. J Microbiol Microb Res 1:7–12
Eveillard M, De Lassence A, Lancien E, Barnaud G, Ricard JD, Joly-Guillou ML (2006) Evaluation of a strategy of screening multiple anatomical sites for methicillin-resistant Staphylococcus aureus at admission to a Teaching Hospital. Infect Control Hosp Epidemiol 27:181–184
Filice GA, Nyman JA, Lexau C, Lees CH, Bockstedt LA, Como-Sabetti K et al (2010) Excess costs and utilization associated with methicillin resistance for patients with Staphylococcus aureus infection. Infect Control Hosp Epidemiol 31:365–373
Franzetti F, Grassini A, Piazza M, Degl’innocenti M, Bandera A, Gazzola L et al (2006) Nosocomial bacterial pneumonia in HIV-infected patients: risk factors for adverse outcome and implications for rational empiric antibiotic therapy. Infection 34:9–16
Furuno JP, Johnson JK, Schweizer ML, Uche A, Stine OC, Shurland SM et al (2011) Community-associated methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis among HIV patients: a cohort study. BMC Infect Dis 11:1–7
Government of Western Australia Department of Health (2013). Infection Prevention and Control of methicillin-resistant Staphylococcus aureus (MRSA) in Western Australian Healthcare Facilities. Western Australia: Healthcare Associated Infection Unit (HAIU), Communicable Disease Control Directorate, Department of Health
Heyssel SK, Shenoi SV, Catterick K, Thomas TA, Friedland G (2011) Prevalence of methicillin-resistant Staphylococcus aureus nasal carriage among hospitalized patients with tuberculosis in rural KwaZulu-Natal. S Afr Med J 101:332–334
Hidron AI, Kemperk R, Moan A, Rimland D (2010) Methicillin-resistant Staphylococcus aureus in HIV-infected patients. Infect Drug Resist 3:73–86
Kejelaa T, Bacha K (2013) Prevalence and antibiotic susceptibility pattern of methicillin-resistant Staphylococcus aureus (MRSA) among Primary school children and prisoners in Jimma Town. Ann Clin Microbiol Antimicrob 12:1–11
Kumar S, Bandopadhyay M, Banerjee P, Laskar S (2013) Nasal methicillin-resistant Staphylococcus aureus colonization in HIV-infected patients from Eastern India. Saudi J Health Sci 2:14–17
Kyaw WM, Lee LK, Siong WC, Li Ping AC, Ang B, Leo YS (2012) Prevalence of and risk factors for MRSA colonization in HIV-positive outpatients in Singapore. AIDS Res Ther 9:1–6
Lee NE, Taylor MM, Bancroft E, Ruane PJ, Morgan M, McCoy L et al (2005) Risk factors for community-associated methicillin-resistant Staphylococcus aureus skin infections among HIV-positive men who have sex with men. Clin Infect Dis 40:1529–1534
Lowy FD (1998) Staphylococcus aureus infections. N Engl J Med 1998(339):520–532
Mertz D, Frei R, Jaussi B, Tietz A, Stebler C, Fluckiger U et al (2007) Throat swabs are necessary to reliably detect carriers of Staphylococcus aureus. Clin Infect Dis 45:475–477
Miller M, Cespedes C, Vavagiakis P, Klein RS, Lowy FD (2003) Staphylococcus aureus colonization in a community sample of HIV-infected and HIV-uninfected drug users. Eur J Clin Microbiol Infect.Dis 22:463–469
National Clinical Effectiveness Committee (2013) Prevention and control methicillin-resistant Staphylococcus aureus: national clinical guide line No. 2. Royal College of Physicians Ireland, Dublin, pp 1–20
Onorato M, Borucki MJ, Baillargeon G, Paar DP, Freeman DH, Cole CP et al (1999) Risk factors for colonization or infection due to methicillin-resistant Staphylococcus aureus in HIV-positive patients: a retrospective case-control study. Infect Control Hosp Epidemiol 20:26–30
Otto M (2012) MRSA virulence and spread. Cell Microbiol 14:1513–1521
Pandey R, Verma R (2008) Samples allocation in different Strata for impact evaluation of developmental programme. Rev Bras Biom 26:103–112
Popovich KJ, Weinstein RA, Aroutcheva A, Rice T, Hota B (2010) Community-associated methicillin resistant Staphylococcus aureus and HIV: interesting epidemics. Clin Infect Dis 50:979–987
Shahin R, Johnson IL, Jamieson F, Mcgeer A, Tollkin J, Ford-Jones EL (1999) Methicillin-resistant Staphylococcus aureus carriage in a child care following a case of disease. Arch Pediatr Adolesc Med 153:864–868
Shibabaw A, Abebe T, Mihret A (2013) Nasal carriage rate of methicillin-resistant Staphylococcus aureus among Dessie Referral Hospital health care workers; Dessie, Northeast Ethiopia. Antimicrob Resist Infect 2:1–5
Tumbarello M, Donati KG, Tacconelli E, Citton R, Spanu T, Leone F et al (2002) Risk factors and predictors of mortality of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in HIV-infected patients. J Antimicrob Chemother 50:375–382
Villacian JS, Barkham T, Earnest A, Paton NI (2004) Prevalence of and risk factors for nasal colonization with Staphylococcus aureus among human immunodeficiency virus-positive outpatients in Singapore. Infect Control Hosp Epidemiol 25:438–440
Wertheim HF, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh HA, Nouwen JL (2005) The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis 5:751–762